Community Acquired Pneumonia Therapeutic Pipeline Analyzed in New Global Markets Direct Report Now Available at

08 Jan 2013 • by Natalie Aster

LONDON – One of the most common diseases on a global scale, community acquired pneumonia (CAP) is especially dangerous for elderly people. In the USA alone, there are around 3.8 million cases of the disease on a yearly basis. In the UK, CAP is amid the main causes of death, with over 82,000 hospital admissions annually in the country.

New drugs for treatment of CAP are approved each year. In H2 2012, Zinforo (otherwise known as ceftaroline fosamil) obtained marketing authorization from the European Commission. A number of antibiotics (e.g. solithromycin) are currently undergoing clinical development.

New market research report “Community Acquired Pneumonia – Pipeline Review, H2 2012” worked out by Global Markets Direct delves deep into the therapeutic scenario for community acquired pneumonia. The study offers valuable data on products under development and the most recent news and deals relating to the products. The report provides a complete overview of pipeline products for community acquired pneumonia (on the basis of various stages of development). Besides, it contains information on the top discontinued pipeline projects and examines key market participants.

Report Details:

Community Acquired Pneumonia – Pipeline Review, H2 2012
Published: December, 2012
Pages: 39
Price: US$ 2,000.00

More In-Demand Healthcare Market Research Reports by Global Markets Direct Include:

More market research reports by the publisher can be found at Global Markets Direct page.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970